MIRM Mirum Pharmaceuticals, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1759425 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY42.2%
TTM net income YoY-2,082.1%
TTM EPS YoY-1,622.6%
Revenue 3-yr CAGR66.7%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-133.6%
Net margin-134.8%
FCF margin-40.8%
EBITDA margin-129.6%
Returns
ROE-760.0%
ROA-99.8%
ROIC (approx.)—
Asset turnover0.74x
Leverage & solvency
Liabilities / assets105.3%
Debt / equity—
Current ratio2.07x
Interest coverage-78.36x
Cash quality & payout
Operating cash flow / net income0.30x
Accruals ratio-69.8%
Payout ratio—
Capex / revenue0.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $185.72M | $176.24M | $159.88M | $148.93M | $133.01M | $127.78M | $111.58M | $99.41M |
| R&D expense | $107.93M | $90.53M | $97.91M | $51.11M | $42.96M | $46.07M | $41.04M | $44.03M |
| SG&A expense | $88.86M | $81.47M | $96.33M | $74.13M | $61.91M | $63.29M | $57.71M | $56.83M |
| Operating income | -$59.75M | -$42.54M | -$789.47M | -$4.57M | $2.60M | -$4.99M | -$15.18M | -$24.22M |
| Interest expense | $1.61M | $2.62M | $3.62M | $3.60M | $3.61M | $3.59M | $3.60M | $3.58M |
| Pretax income | -$40.23M | -$65.54M | -$789.68M | -$4.96M | $2.64M | -$5.46M | -$13.65M | -$24.37M |
| Income tax | $538,000 | $1.69M | $475,000 | $767,000 | -$262,000 | $402,000 | $1.03M | -$576,000 |
| Net income | -$40.77M | -$67.23M | -$790.15M | -$5.73M | $2.90M | -$5.86M | -$14.68M | -$23.79M |
| EBITDA | -$52.86M | -$35.60M | -$782.59M | $1.51M | $8.66M | $1.07M | -$9.13M | -$18.17M |
| EPS (basic) | -0.62 | -1.06 | -13.43 | — | 0.06 | -0.12 | -0.30 | — |
| EPS (diluted) | -0.87 | -1.06 | -13.43 | — | 0.05 | -0.12 | -0.30 | — |
| Weighted avg. shares (diluted) | 66.05M | 63.37M | 58.85M | — | 56.99M | 49.73M | 48.89M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $243.19M | $330.73M | $324.91M | $296.68M | $282.02M | $228.12M | $211.82M | $222.50M |
| Short-term investments | $130.50M | $107.56M | $61.35M | $86.64M | $93.53M | $76.43M | $65.85M | $57.81M |
| Receivables | $156.35M | $145.36M | $133.11M | $123.33M | $107.13M | $106.84M | $95.85M | $78.29M |
| Inventory | $25.49M | $25.77M | $25.52M | $24.89M | $24.02M | $22.94M | $22.42M | $22.40M |
| Current assets | $586.63M | $636.31M | $569.44M | $549.68M | $530.58M | $453.40M | $410.82M | $392.79M |
| PP&E, net | $3.25M | $2.25M | $2.41M | $1.86M | $1.28M | $1.18M | $1.11M | $1.14M |
| Intangibles | $275.65M | $247.39M | $254.15M | $260.92M | $231.90M | $237.87M | $243.84M | $249.82M |
| Total assets | $1.03B | $1.04B | $890.92M | $842.81M | $785.12M | $725.83M | $690.25M | $670.75M |
| Current liabilities | $283.08M | $222.79M | $272.82M | $205.80M | $160.36M | $144.80M | $127.58M | $126.55M |
| Total liabilities | $1.08B | $1.06B | $648.42M | $528.12M | $493.07M | $470.67M | $456.99M | $445.11M |
| Shareholders' equity | -$54.19M | -$10.42M | $242.49M | $314.69M | $292.05M | $255.16M | $233.26M | $225.64M |
| Shares outstanding | 65.21M | 64.75M | 60.93M | 51.90M | 51.31M | 50.06M | 49.45M | 48.34M |
| Cash flow statement | ||||||||
| Operating cash flow | -$4.31M | -$44.25M | -$228.76M | $6.07M | $39.68M | $12.04M | -$1.96M | -$5.07M |
| Capital expenditure | $1.30M | $23,000 | $664,000 | $600,000 | $187,000 | $126,000 | $41,000 | $20,000 |
| Free cash flow | -$5.62M | -$44.27M | -$229.43M | $5.47M | $39.49M | $11.91M | -$2.00M | -$5.09M |
| Investing cash flow | -$28.87M | -$159.99M | -$11.57M | $1.01M | -$2.23M | -$6.60M | -$16.13M | $641,000 |
| Financing cash flow | -$54.34M | $211.44M | $270.08M | $9.00M | $16.10M | $8.69M | $6.36M | $5.34M |
| Depreciation & amortization | $6.89M | $6.94M | $6.87M | $6.07M | $6.06M | $6.06M | $6.05M | $6.06M |
| Stock-based compensation | $33.31M | $30.57M | $36.20M | $19.03M | $18.13M | $18.47M | $15.80M | $13.25M |
Free plan shows the latest 8 periods; Pro shows all 33 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.